Cargando…

1542. MR-proADM Biomarker Predicts COVID-19 Clinical Outcomes: a US-based Cohort Study

BACKGROUND: Mid-regional proadrenomedullin (MR-proADM) is a biomarker released following endothelial damage. Our study aimed to investigate baseline MR-proADM as a predictor of a wider range of clinical outcomes of varying severity in patients admitted with COVID-19 from a US-based multicenter trial...

Descripción completa

Detalles Bibliográficos
Autor principal: Mansour, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751617/
http://dx.doi.org/10.1093/ofid/ofac492.097